Table 2 Impact of prior enalapril and l-NAME treatment on body weight (BW), heart weight (HW) and heart weight-to-body weight ratio (HW/BW)

From: Time course of cardiac inflammation during nitric oxide synthase inhibition in SHR: impact of prior transient ACE inhibition

 

BW (g)

HW (g)

HW/BW (g kg−1)

Infarct/LV (%)

C+L0

319±2.0

1.08±0.012

3.37±0.025

0.33±0.209

C+L3

329±2.9

1.12±0.015

3.39±0.047

0.40±0.146

C+L7

333±6.0

1.13±0.015

3.40±0.038

5.66±2.492

C+L10

314±5.7

1.17±0.027*

3.73±0.106*

2.64±1.742

E+L0

319±8.4

0.93±0.021‡

2.93±0.031‡

0.11±0.047

E+L3

326±8.4

1.03±0.020†‡

3.15±0.051†‡

0.16±0.104

E+L7

328±5.6

1.03±0.017†‡

3.14±0.033†‡

5.88±3.124

E+L10

333±8.2

1.10±0.023†

3.29±0.050†‡

0.71±0.387

  1. Abbreviations: ANOVA, analysis of variance; l-NAME, l-arginine methyl ester; LV, left ventricle.
  2. Values are presented as mean±s.e.m. Bonferroni post-test following two-way ANOVA: *P<0.05 vs. C+L0, †P<0.05 vs. E+L0, ‡P<0.05 vs. age-matched C+L. HW/BW: two-way ANOVA: pre-treatment P<0.05, time P<0.05, interaction P=0.10. Infarct/LV: two-way ANOVA: time P<0.05.
Back to article page